McAdam LLC’s Myovant Sciences Ltd. MYOV Stock Holding History

McAdam LLC’s Portfolio MYOV Stock Details MYOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-35	Closed	-$1K	–	754
2018 Q2	$1K	Hold	35	–	–	﹤0.01%	608
2018 Q1	$1K	Buy	+35	New	+$533	﹤0.01%	727

Other funds holding MYOV

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

McAdam LLC's MYOV Position: Q3 2018 in Review

McAdam LLC sold out of Myovant Sciences Ltd. (MYOV) in Q3 2018, closing a stake of 35 shares — an estimated $1K sold.

McAdam LLC first reported a position in MYOV in Q1 2018 and held it in 2 quarters. The position peaked at $1K in Q2 2018. 35 funds tracked by Wall St. Rank hold MYOV as of Q3 2018.

McAdam LLC reported no remaining Myovant Sciences Ltd. position as of Q3 2018 after selling out during the quarter.
McAdam LLC sold 35 Myovant Sciences Ltd. shares in Q3 2018, an estimated $1K.
McAdam LLC first reported a position in Myovant Sciences Ltd. in Q1 2018 and held it in 2 quarters.
McAdam LLC's Myovant Sciences Ltd. position peaked at $1K in Q2 2018.
35 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q3 2018.

Based on McAdam LLC's 13F filing for Q3 2018, filed 10 Oct 2018.